Aurinia Pharmaceuticals Inc (AUPH)

[northern vortex]

moosedogger - The power of your analyses lies in your second-last sentence. The trajectory of the launch over one full quarter of sales will be very important in the premium paid for the company. It will show the degree of acceptance of the product by the LN community, their nephrologists and the medical insurance providers.

Furthermore, consider the number of companies that have failed to bring an LN product to market. I strongly believe that many of them will be very interested in this product.

The buyer will not only be getting a breakthrough, SOC product; also included in the package will be a first-class marketing and sales team.

I would agree with you that the current SP (perhaps influenced by IJUN) does not lend itself to some big speculative premium. However, a successful sale of the company will be based on good execution and the current conditions in the M&A market for a large, unmet, medical need. It has taken many years to get to this point. AUP has been very methodical and it is not about to blow it in the 11th hour. We will get full price for the company.